Mapping the global research landscape of risankizumab: a decade (2016-2025) of multi-database bibliometric analysis and emerging frontiers.

Risankizumab is a humanized monoclonal antibody that selectively targets the interleukin-23 p19 subunit. It has demonstrated lasting therapeutic effects in a variety of diseases. Previous bibliometric studies have carried out macro-level mapping in the field of biologic agents for psoriasis. However, no systematic knowledge-map analysis has been conducted specifically for risankizumab. To fill this research gap, this study combines bibliometric and narrative pharmacological approaches. Relevant literature published between January 2016 and December 2025 was retrieved from the Web of Science Core Collection and the Scopus database. Two researchers independently screened the literature and included a total of 2,053 eligible publications, then performed the analyses using Bibliometrix, VOSviewer, CiteSpace, and Microsoft Excel. The results show that the number of drug-related research publications has increased substantially, from only 9 articles in 2016 to nearly 500 in 2025. The United States ranks first in publication volume (n = 1,130), followed by AbbVie as the most productive institution (n = 147) and Matteo Megna as the most prolific author (n = 55). Relevant findings are mainly published in journals such as the International Journal of Molecular Sciences, Annals of the Rheumatic Diseases, JAMA, and The Lancet. Keyword co-occurrence analysis identified 20 independent clusters (Q = 0.9069, S = 0.9776). By integrating bibliometric data with pharmacological background, this study presents the first comprehensive knowledge atlas of the risankizumab research field, offering practical references for future investigations on this drug.